1. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics 
Cheryl Bushnell, MD, MHS, Louise Zimmer, MA, MPH, Lee Schwamm, MD, Larry B. Goldstein, MD, Nancy Clapp-Channing, MPH, Tina Harding, RN, BSN, Laura Drew, RN, BSN, Xin Zhao, MS, Eric Peterson, MD, MPH 
American Heart Journal 
Volume 157, Issue 3, Pages e2 (March 2009)
DOI: /j.ahj
Copyright © 2009 Mosby, Inc. Terms and Conditions

2. Figure 1
Persistence diagram. Persistence represents the duration of time from initiation to discontinuation of therapy. Patients on a medication at 1 study time point who report taking the medication at a further study time point are considered to be persistent through that period (dark green arrows). Patients for whom the timing of medication initiation is unknown, that is, begun after a study time point, are considered initiators (indicated by dotted green line). Unknown end date for medication use is indicated by a dotted red line.
American Heart Journal  , e2DOI: ( /j.ahj )
Copyright © 2009 Mosby, Inc. Terms and Conditions